Michael Elliot Shankman - 15 May 2025 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Chief Financial Officer
Signature
/Michael Shankman/
Issuer symbol
LEXX
Transactions as of
15 May 2025
Net transactions value
$0
Form type
4
Filing time
16 May 2025, 16:51:22 UTC
Previous filing
02 Oct 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shankman Michael Elliot Chief Financial Officer 406 NATALIE LANE, DANVILLE /Michael Shankman/ 16 May 2025 0002035175

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +50,000 +100% $0.000000 100,000 15 May 2025 Common Shares 50,000 $1.04 Direct
holding LEXX Stock Options 50,000 15 May 2025 Common Shares 50,000 $3.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20,000 options are exercisable as of February 28, 2025, an additional 15,000 options are exercisable on August 31, 2025 and the remaining 15,000 options are exercisable on August 31, 2026